Bli medlem
Bli medlem

Du är här

2021-03-04

ExpreS2ion Biotechnologies: ExpreS2ion will participate at key industry and investor events in March 2021

ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate and hold presentations at key industry and investor events in March, all of which will be held digitally. These include Aktiespararna's Aktiedagen (March 16), the St. Gallen International Breast Cancer Conference (March 17-21), and BIO-Europe Spring (March 22-25).

By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS[2] technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below.

Aktiespararna's Aktiedagen, March 16, at 11.00-11.30

See the company presentation by our CEO Bent U. Frandsen at this investor event. It is possible to follow the event online, or attend the meeting by reserving a seat at Aktiespararna's website (https://www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-16-17-mars-2021-digitalt-evenemang).

17[th] St. Gallen International Breast Cancer Conference, March 17-21
To learn more about the preclinical-stage ES2B-C001 HER2-cVLP breast cancer vaccine, pre-arrange meetings via email on info@expreS2ionbio.com.More information is available at the event website (https://www.oncoconferences.ch/events/bcc-2021/).

BIO-Europe Spring, March 22-25, Digital
To pre-arrange business meetings with ExpreS[2]ion representatives, please contact us via email on info@expreS2ionbio.com.More information is available at BIO-Europe's website (https://ebdgroup.knect365.com/bioeurope-spring/).

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se
 

For further information about ExpreS[2]ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.